Radioactive material from America's first atomic bomb experiments has been turned into a surprising treatment for multiple ...

Curadh MTR Inc. ("Curadh") and Alpha Fusion, Inc. ("Alpha Fusion") will present on the clinical development of radiopharmaceutical products at the upcoming 4th Targeted Radiopharmaceuticals Summit US ...

Radioactive material from America's first atomic bomb experiments has been turned into a surprising treatment for multiple ...

Neutrophils, once considered simple foot soldiers of innate immunity, are now recognized as complex players in cancer. This ...

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), a leading U.S. producer of uranium, rare earth elements, and critical minerals, will hold a conference call on Thursday, August 7, 2025, at 9:00 AM ...

Perspective Therapeutics, Inc. ('Perspective” or the 'Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced ...

Cytokine networks demonstrate dual functionality. Cytokines are key regulators of immune homeostasis, but paradoxically, cytokines also function as pathogenic drivers in diseases such as systemic ...

Roche’s Itovebi gets European approval to treat people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation: Basel Thursday, July 24, 2025, 09:00 Hrs [ ...

The first Saturday of May each year marks World Ankylosing Spondylitis (AS) Day, raising awareness of the 54 million patients ...

Market SynopsisThe Global Radiopharmaceuticals Market is valued at USD 6.8 Billion in 2024 and is projected to reach a value of USD 19.15 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

Basel: Roche has received approval from the European Commission for Itovebi (inavolisib), in combination with palbociclib ...